Expertise in
38
conditions

Dr. Sal Vasireddy

Hematology Oncology | Hematology | Oncology
Baptist Cancer Center (Physicians)
80 Humphreys Center Dr Ste 330, 
Memphis, TN 
Offers Telehealth
Expertise in
38
conditions
Baptist Cancer Center (Physicians)
80 Humphreys Center Dr Ste 330, 
Memphis, TN 

Overview

Sal Vasireddy is a Hematologist Oncology specialist and a Hematologist in Memphis, Tennessee. Dr. Vasireddy is highly rated in 38 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Intraductal Papilloma.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in MS

Hospital Affiliations

Baptist Memorial Hospital Union County
Baptist Memorial Hospital Tipton
Methodist Hospitals Of Memphis
Baptist Memorial Hospital Desoto
Baptist Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Baptist Cancer Center (Physicians)
80 Humphreys Center Dr Ste 330, Memphis, TN 38120

Additional Areas of Focus

Dr. Vasireddy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: February 12, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Raymond Osarogiagbon
Expertise in
11
conditions
Dr. Raymond Osarogiagbon
Hematology Oncology | Hematology | Oncology
Expertise in
11
conditions
Dr. Raymond Osarogiagbon
Hematology Oncology | Hematology | Oncology

Laboratory Corporation Of America Holdings

7900 Airways Blvd Bldg B, 
Southaven,, MS 
 (63.9 miles away)
662-349-2442
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raymond Osarogiagbon is a Hematologist Oncology specialist and a Hematologist in Southaven,, Mississippi. Dr. Osarogiagbon is highly rated in 11 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Lung Adenocarcinoma, and Endoscopy.

Expertise in
13
conditions
Dr. Amar Gajjar
Hematology | Oncology
Expertise in
13
conditions
Dr. Amar Gajjar
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (73.5 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Gajjar is highly rated in 13 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Expertise in
15
conditions
Dr. Marcin Wlodarski
Hematology | Oncology
Expertise in
15
conditions
Dr. Marcin Wlodarski
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (73.5 miles away)
888-226-4343
Languages Spoken:
English
See accepted insurances

Marcin Wlodarski is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Wlodarski is highly rated in 15 conditions, according to our data. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Dyskeratosis Congenita, Bone Marrow Transplant, and Splenectomy.

Frequently Asked Questions about Dr. Sal Vasireddy

How do I make an appointment with Dr. Sal Vasireddy?

You can book an appointment with Dr. Sal Vasireddy by calling their office at 901-752-6131. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sal Vasireddy a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sal Vasireddy is classified as an Distinguished expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sal Vasireddy specialize in?

While Dr. Sal Vasireddy is a Hematology Oncology, they have specific expertise in Pleuropulmonary Blastoma, Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Sal Vasireddy accept my insurance?

Dr. Sal Vasireddy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 901-752-6131 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasireddy's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 128 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile